马来酸丙氯拉嗪预防急性高山病的随机对照试验研究方案
急性高山病(AMS)是在快速上升至高海拔时可能发生的头痛、恶心、呕吐、头晕和乏力等症状,可能进展为致命疾病。该随机双盲试验将未习服的18岁及以上成人随机分配接受口服马来酸丙氯拉嗪或安慰剂,每日三次、持续24小时,在快速上升至4348米的过程中给药,并在到达最高海拔当晚和次晨使用路易斯湖问卷评估主要结局和AMS发生情况。
要点
- 马来酸丙氯拉嗪是一种一线偏头痛治疗药物,可能通过早期终止偏头痛机制及呼吸兴奋作用预防AMS。
- 试验纳入未习服的18岁及以上成人,在快速上升至4348米过程中每日三次口服给药24小时。
- 主要结局采用路易斯湖问卷在到达最高海拔当晚和次晨评估AMS的发生。
核心结论
- 马来酸丙氯拉嗪可能有效预防急性高山病,尚需随机对照试验验证。
研究设计与样本
- 随机双盲试验,参与者随机接受口服马来酸丙氯拉嗪或安慰剂,每日三次给药24小时,在快速上升至4348米过程中进行,参与者为未习服的18岁及以上成人并在该海拔过夜。
主要发现
- 原文未报告结果。
关键数值与推荐
- 主要结局和AMS的存在采用路易斯湖问卷定义,并在到达最高海拔当晚和次晨评估。
临床怎么用
- 目前乙酰唑胺是AMS化学预防的首选方案,自20世纪70年代以来已被研究和应用,但可能存在难以耐受的副作用。
- 需要其他更有效且副作用更可耐受的选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute mountain sickness (AMS) is a debilitating condition that individuals may develop on ascent to high altitude. It is characterized by headache, nausea, vomiting, dizziness, and fatigue with the potential to progress to fatal disease. Although the pathophysiology of AMS remains unclear, proposed mechanisms are hypothesized to be similar to migraine. Prochlorperazine, a first-line treatment for acute migraine, has been shown to abort migraine early and thus may be effective in preventing AMS. Its action as a respiratory stimulant additionally makes it a promising novel agent for AMS prevention. METHODS: In this randomized double-blinded trial, participants will be randomized to receive oral prochlorperazine maleate or placebo for 24 h of three times daily dosing on a rapid ascent to 4348 m. Participants will be adults, aged 18, and older who are unacclimatized. Participants will remain at this elevation overnight. The Lake Louise Questionnaire will be utilized to define the primary outcome and presence of AMS and will be assessed the evening of and morning after ascent to peak altitude. DISCUSSION: Currently, acetazolamide is the preferred option for the chemoprophylaxis of AMS, which has been studied and utilized since the 1970s and involves potential prohibitive side effects. Other more efficacious options with more tolerable side effects are needed. Preventing AMS has the potential to limit both the morbidity and mortality associated with developing AMS and more serious diseases (notably high-altitude cerebral edema). Additionally, there is a substantial economic and environmental impact of AMS that could be prevented. TRIAL REGISTRATION: Clinicaltrial.gov, NCT06450899. Registered on June 2024.
引用
- Small E, Goldberg E, Musi M, et al. Prochlorperazine maleate versus placebo for the prevention of acute mountain sickness: study protocol for a randomized controlled trial. Trials. 2024. PMID: 39574186. doi:10.1186/s13063-024-08592-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。